Literature DB >> 10716986

Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein.

Z E Sauna1, S V Ambudkar.   

Abstract

P-glycoprotein (Pgp) is an ATP-dependent hydrophobic natural product anticancer drug efflux pump whose overexpression confers multidrug resistance to tumor cells. The work reported here deals with the elucidation of the energy requirement for substrate interaction with Pgp during the catalytic cycle. We show that the K(d) (412 nM) of the substrate analogue [(125)I]iodoarylazidoprazoin for Pgp is not altered by the presence of the nonhydrolyzable nucleotide 5'-adenylylimididiphosphate and vanadate (K(d) = 403 nM). Though binding of nucleotide per se does not affect interactions with the substrate, ATP hydrolysis results in a dramatic conformational change where the affinity of [(125)I]iodoarylazidoprazoin for Pgp trapped in transition-state conformation (Pgp x ADP x vanadate) is reduced >30-fold. To transform Pgp from this intermediate state of low affinity for substrate to the next catalytic cycle, i.e., a conformation that binds substrate with high affinity, requires conditions that permit ATP hydrolysis. Additionally, there is an inverse correlation (R(2) = 0.96) between 8AzidoADP (or ADP) release and the recovery of substrate binding. These results suggest that the release of nucleotide is necessary for reactivation but not sufficient. The hydrolysis of additional molecule(s) of ATP (or 8AzidoATP) is obligatory for the catalytic cycle to advance to completion. These data are consistent with the observed stoichiometry of two ATP molecules hydrolyzed for the transport of every substrate molecule. Our data demonstrate two distinct roles for ATP hydrolysis in a single turnover of the catalytic cycle of Pgp, one in the transport of substrate and the other in effecting conformational changes to reset the pump for the next catalytic cycle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716986      PMCID: PMC15960          DOI: 10.1073/pnas.97.6.2515

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  A rapid, sensitive, and specific method for the determination of protein in dilute solution.

Authors:  W Schaffner; C Weissmann
Journal:  Anal Biochem       Date:  1973-12       Impact factor: 3.365

2.  The barriers in protein folding.

Authors:  T R Sosnick; L Mayne; R Hiller; S W Englander
Journal:  Nat Struct Biol       Date:  1994-03

3.  Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein.

Authors:  I L Urbatsch; M K al-Shawi; A E Senior
Journal:  Biochemistry       Date:  1994-06-14       Impact factor: 3.162

4.  Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein.

Authors:  F J Sharom; X Yu; C A Doige
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

5.  Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities.

Authors:  T W Loo; D M Clarke
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

6.  P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site.

Authors:  I L Urbatsch; B Sankaran; J Weber; A E Senior
Journal:  J Biol Chem       Date:  1995-08-18       Impact factor: 5.157

7.  Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12.

Authors:  L M Greenberger
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

8.  Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin.

Authors:  D I Morris; L M Greenberger; E P Bruggemann; C Cardarelli; M M Gottesman; I Pastan; K B Seamon
Journal:  Mol Pharmacol       Date:  1994-08       Impact factor: 4.436

9.  Covalent inhibitors of P-glycoprotein ATPase activity.

Authors:  M K al-Shawi; I L Urbatsch; A E Senior
Journal:  J Biol Chem       Date:  1994-03-25       Impact factor: 5.157

10.  N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells.

Authors:  A R Safa; M Agresti; D Bryk; I Tamai
Journal:  Biochemistry       Date:  1994-01-11       Impact factor: 3.162

View more
  69 in total

Review 1.  Structure and function of efflux pumps that confer resistance to drugs.

Authors:  M Ines Borges-Walmsley; Kenneth S McKeegan; Adrian R Walmsley
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

2.  Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.

Authors:  Ke-Jun Liu; Jie-Hua He; Xiao-Dong Su; Hong-May Sim; Jing-Dun Xie; Xing-Gui Chen; Fang Wang; Yong-Ju Liang; Satyakam Singh; Kamlesh Sodani; Tanaji T Talele; Suresh V Ambudkar; Zhe-Sheng Chen; Hai-Ying Wu; Li-Wu Fu
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

3.  The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors:  Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

4.  A structural analysis of asymmetry required for catalytic activity of an ABC-ATPase domain dimer.

Authors:  Jelena Zaitseva; Christine Oswald; Thorsten Jumpertz; Stefan Jenewein; Alexander Wiedenmann; I Barry Holland; Lutz Schmitt
Journal:  EMBO J       Date:  2006-07-06       Impact factor: 11.598

5.  Single-turnover kinetic experiments confirm the existence of high- and low-affinity ATPase sites in Escherichia coli Lon protease.

Authors:  Diana Vineyard; Jessica Patterson-Ward; Irene Lee
Journal:  Biochemistry       Date:  2006-04-11       Impact factor: 3.162

Review 6.  The mechanism of action of multidrug-resistance-linked P-glycoprotein.

Authors:  Z E Sauna; M M Smith; M Müller; K M Kerr; S V Ambudkar
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 7.  Overview: ABC transporters and human disease.

Authors:  M M Gottesman; S V Ambudkar
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 8.  Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies.

Authors:  Eduardo E Chufan; Hong-May Sim; Suresh V Ambudkar
Journal:  Adv Cancer Res       Date:  2015-01-08       Impact factor: 6.242

9.  Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.

Authors:  Shahrooz Vahedi; Eduardo E Chufan; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2017-07-17       Impact factor: 5.858

10.  Design, synthesis, and biological evaluation of (S)-valine thiazole-derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P-glycoprotein (ABCB1).

Authors:  Satyakam Singh; Nagarajan Rajendra Prasad; Khyati Kapoor; Eduardo E Chufan; Bhargav A Patel; Suresh V Ambudkar; Tanaji T Talele
Journal:  Chembiochem       Date:  2013-11-29       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.